Daxor Corporation Common Stock
DXRDaxor Corporation (DXR) is a medical device company specializing in blood volume measurement technology. It is known for its BVA-100 Blood Volume Analyzer, which provides precise blood volume readings to aid in the diagnosis and management of various health conditions, including anemia, heart failure, and blood disorders. The company has a long-standing history of developing and commercializing innovative diagnostic tools within the healthcare industry.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 12, 2018 | $0.03 | 2018-01-05 | 2018-01-08 |
| December 29, 2016 | $0.03 | 2016-12-20 | 2016-12-22 |
| December 29, 2015 | $0.04 | 2015-12-18 | 2015-12-22 |
| December 26, 2014 | $0.03 | 2014-12-04 | 2014-12-08 |
| December 27, 2013 | $0.05 | 2013-12-05 | 2013-12-09 |
Dividends Summary
- Consistent Payer: Daxor Corporation Common Stock has rewarded shareholders with 18 dividend payments over the past 10 years.
- Total Returned Value: Investors who held DXR shares during this period received a total of $4.48 per share in dividend income.
- Latest Payout: The most recent dividend of $0.03/share was paid 3109 days ago, on January 12, 2018.
- Yield & Schedule: DXR currently pays dividends yearly with an annual yield of 0.28%.
- Dividend Growth: Since 2008, the dividend payout has decreased by 88.0%, from $0.25 to $0.03.
Company News
Daxor Corporation will exhibit its FDA-cleared Blood Volume Analyzer (BVA) for the first time at the 14th Annual Dysautonomia International Conference (July 9-12, 2026) in Texas. The company emphasizes how BVA provides objective plasma and red blood cell data to improve dysautonomia therapy, representing a shift from subjective symptom tracking t...
Daxor Corporation announced a definitive agreement to sell 765,958 shares of common stock at $11.75 per share to fundamental investors, raising approximately $9 million in gross proceeds. The offering is expected to close on January 26, 2026, with net proceeds intended for general corporate purposes and working capital. Lake Street Capital Market...
Daxor Corporation will participate in the Maxim Growth Summit in New York City, presenting its innovative Blood Volume Analysis (BVA) technology to institutional investors and featuring one-on-one meetings with potential investors.
Daxor Corporation, a leader in blood volume measurement technology, will showcase its innovative Blood Volume Analysis (BVA) at the MedAxiom Cardiovascular Transforum Spring 2025 conference. WellStar Health System will present findings on how BVA-driven strategies significantly reduced kidney injury following LVAD implantation.
Daxor Corporation, the global leader in blood volume measurement technology, presented new data from Duke University at the American College of Cardiology's annual conference. The research reinforced the value of Daxor's blood volume analysis (BVA) technology in managing heart failure patients, highlighting its superiority over traditional pressu...
